PharmaResearch Co (214450) Fair Value & Analysis
Healthcare · KR · Market cap 3.5T KRW
Fair value as of: Jul 18, 2026
From 26 valuation models · updated 22 days ago
Share price +15.7% over the past month.
A strong business, but screening 19% overvalued on our models.
What matters now
- A high-quality business (quality 78/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (230,750 KRW to 951,003 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range 54,109 KRW – 708,934 KRW · fair‑value band 230,750 KRW – 951,003 KRW · the 378,500 KRW price screens above the 308,302 KRW fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
PharmaResearch Co (214450) currently trades at 378,500 KRW, while our model-based Fair Value estimate is 308,302 KRW, implying the stock looks roughly 18.6% overvalued today. The Quality Score stands at 78/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PharmaResearch Co generated revenue of 565B KRW at a net margin of 31.2%. Revenue grew 25.0% year over year. It earns a return on equity of 27.3%. Net debt stands at 19.8B KRW. Fundamentals as of Jul 18, 2026
Our scenario range runs from 230,750 KRW (bear case) to 951,003 KRW (bull case); at 378,500 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 36% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -19%, 214450 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (731,541 KRW) versus Dividend Discount (19,419 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 77 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea.
Full company description
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PharmaResearch Co reported revenue of 536B KRW in FY2025 versus 154B KRW in FY2021, a compound +36.6%/yr. Reported net income was 165B KRW in FY2025, compounding +37.1%/yr from FY2021.
214450 screens 19% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare PharmaResearch Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PharmaResearch Co (214450) overvalued or undervalued?
What is the fair value of 214450?
What is the quality score of 214450?
What is the revenue of PharmaResearch Co (214450)?
What is the net profit margin of 214450?
Does PharmaResearch Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PharmaResearch Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.